B-Cell Lymphomas Coverage from Every Angle


FDA Approves Epcoritamab-bysp in Treatment of Resistant DLBCL
AACR 2023: Can Machine Learning Improve Predictive Prognostics in Mantle Cell Lymphoma?
AACR 2023: Identifying a CD5 Gene Signature for Sensitivity to BTK Inhibition in DLBCL
FDA Approves Polatuzumab Vedotin in Combination Therapy for B-Cell Lymphomas
AACR 2023: Combination of Epcoritamab and Standard-of-Care Therapies for DLBCL
FDA Brief: Cell Therapy Approved to Reduce Infection Risk After Stem Cell Transplantation
PMRT5-Directed Therapy for Mantle Cell Lymphoma With High Mutation Burden: Early-Phase Study Findings
A Newly Described Variant of Follicle Center Lymphoma Involving the Female Genital Tract
Brexucabtagene Autoleucel in Resistant Mantle Cell Lymphoma: Real-World Versus ZUMA-2 Data
Case Report Features Novel Therapeutic Strategy for Chemotherapy-Resistant DLBCL
ELARA Trial: Is Tisagenlecleucel of Benefit in Relapsed or Refractory Follicular Lymphoma?
Using an AI Algorithm to Measure Prognostic Biomarkers in DLBCL
Impact of Eligibility Criteria by Race/Ethnicity in First-Line Trials of DLBCL
Final Analysis of Novel Triplet Combination in Resistant Follicular Lymphoma
FDA Grants Accelerated Approval to Pirtobrutinib for Resistant Mantle Cell Lymphoma
Long-Term Update on Upfront Rituximab Versus ‘Watch and Wait’ in Follicular Lymphoma
Role of MRD in Rituximab Maintenance for Older Patients With Mantle Cell Lymphoma
Combination of Zandelisib Plus Zanubrutinib in Treatment of B-Cell Malignancies
Adding Acalabrutinib to Combination Therapy for Mantle Cell Lymphoma
Priority Review Granted by the FDA for Glofitamab in Treatment of Large B-Cell Lymphoma
ASH 2022: Phase II Study Results With Mosunetuzumab in Resistant Follicular Lymphoma
ASH 2022: Updated ELARA Trial Results of Tisagenlecleucel Therapy for Advanced Follicular Lymphoma
ASH 2022: Does Addition of Lenalidomide Boost Rituximab Efficacy in Mantle Cell Lymphoma?
FDA Brief: Mosunetuzumab Granted Approval in Treatment of Resistant Follicular Lymphoma
ASH 2022: Does Time to Relapse Affect Response to Second-Line Chemotherapy in DLBCL?
ASH 2022: Can Ibrutinib Combination Replace ASCT for Some Younger Patients With Mantle Cell Lymphoma?
ASH 2022: POLARIX Trial Focuses on ctDNA for Risk Profiling in Diffuse Large B-Cell Lymphoma
ASH 2022: Glofitamab Monotherapy for Resistant Mantle Cell Lymphoma
ASH 2022: Could IRF4 Become a Prognostic Marker in Follicular Lymphoma?
Axicabtagene Ciloleucel and Tisagenlecleucel in Resistant DLBCL: Real-World Matched Comparison
Treatment With Tisagenlecleucel for Infants and Toddlers With B-Cell ALL
Epcoritamab Accepted for Priority Review by FDA in Treatment of LBCL

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.